AR128515A1 - Formulación de toxina botulínica líquida y su uso - Google Patents

Formulación de toxina botulínica líquida y su uso

Info

Publication number
AR128515A1
AR128515A1 ARP230100337A ARP230100337A AR128515A1 AR 128515 A1 AR128515 A1 AR 128515A1 AR P230100337 A ARP230100337 A AR P230100337A AR P230100337 A ARP230100337 A AR P230100337A AR 128515 A1 AR128515 A1 AR 128515A1
Authority
AR
Argentina
Prior art keywords
botulinum toxin
present
liquid formulation
liquid
serotype
Prior art date
Application number
ARP230100337A
Other languages
English (en)
Spanish (es)
Inventor
Eisele Karl Dr
- Dr Fink Klaus Heinz
Taylor Harold V Dr
Jatzke Claudia Dr
Khbach Katja Dr
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR128515A1 publication Critical patent/AR128515A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
ARP230100337A 2022-02-15 2023-02-14 Formulación de toxina botulínica líquida y su uso AR128515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22156850 2022-02-15

Publications (1)

Publication Number Publication Date
AR128515A1 true AR128515A1 (es) 2024-05-15

Family

ID=80682748

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100337A AR128515A1 (es) 2022-02-15 2023-02-14 Formulación de toxina botulínica líquida y su uso

Country Status (13)

Country Link
US (1) US20250161186A1 (https=)
EP (1) EP4479012A1 (https=)
JP (1) JP2025504247A (https=)
KR (1) KR20240150786A (https=)
CN (1) CN118829442A (https=)
AR (1) AR128515A1 (https=)
AU (1) AU2023222384A1 (https=)
CA (1) CA3243198A1 (https=)
CO (1) CO2024010938A2 (https=)
IL (1) IL314995A (https=)
MX (1) MX2024009969A (https=)
TW (1) TW202400223A (https=)
WO (1) WO2023156385A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192118A (ja) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
AU4746096A (en) * 1995-06-06 1996-12-24 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
CA3060669A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
MX2021014486A (es) * 2020-03-31 2022-01-04 Obi Pharma Inc Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo.

Also Published As

Publication number Publication date
IL314995A (en) 2024-10-01
US20250161186A1 (en) 2025-05-22
JP2025504247A (ja) 2025-02-06
WO2023156385A1 (en) 2023-08-24
MX2024009969A (es) 2024-09-18
CA3243198A1 (en) 2023-08-24
KR20240150786A (ko) 2024-10-16
TW202400223A (zh) 2024-01-01
EP4479012A1 (en) 2024-12-25
CO2024010938A2 (es) 2024-09-19
CN118829442A (zh) 2024-10-22
AU2023222384A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
AR128515A1 (es) Formulación de toxina botulínica líquida y su uso
AU2017394571B2 (en) Stable liquid composition comprising botulinum toxin
BR112018004642A2 (pt) processo para tratamento capilar
EA201691883A1 (ru) Жидкая композиция, содержащая соединение, нейтрализующее gm-csf
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
MX2018014631A (es) Formulacion de neurotoxina.
RU2019104998A (ru) Жидкая композиция, содержащая ботулотоксин и стабилизирующий агент, и способ её получения
CO2024010940A2 (es) Formulación líquida de toxina botulínica y uso de la misma
EA202092749A1 (ru) Композиции, содержащие аминокислоты, для применения в предотвращении и лечении заболеваний печени
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
MX2021014561A (es) Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.
BR112022013204A2 (pt) Usos de uma composição e de uma preparação combinada
CO2022012868A2 (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
BR112021026076A2 (pt) Composto derivado introduzindo o grupo bifenila no novo ácido aminoalcanoico e composição farmacêutica antifúngica compreendendo o mesmo
BR112019023981A2 (pt) injeção de octreotida
MX2021005925A (es) Proceso y producto lacteo.
NI201900063A (es) Amidas aromáticas de ácido carboxílico
JP2024542906A (ja) ボツリヌス毒素を含む安定した液状製剤
MX2023013070A (es) Formulaciones liquidas ionicas para el tratamiento de enfermedades inflamatorias y autoinmunes.
EA202090908A1 (ru) Вакцина и связанные композиции для лечения пародонтита и способ применения
Kim et al. Effect of calcium lactate on m-calpain activity and protein degradation under oxidising conditions
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
ATE533495T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten gekennzeichnet durch exsudation von serumproteinen
Holden et al. The in vitro action of synthetic crystalline vitamin C (ascorbic acid) on herpes virus